We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Outcomes-Based Pricing as a Tool to Ensure Access to Novel but Expensive Biopharmaceuticals.
- Authors
Blumenthal, Daniel M.; Goldman, Dana P.; Jena, Anupam B.
- Abstract
The article examines the use of outcomes-based pricing as a tool to ensure access to new but costly biopharmaceuticals. It describes cost issues faced by insurers and patients with regard to the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibody lipid-lowering therapies, for atherosclerotic cardiovascular disease or familial hyperlipidemia. It also discusses other advantages of outcomes-based pricing over other pricing models.
- Subjects
DRUG prices; PROPROTEIN convertases; BIOPHARMACEUTICS; PRICING; THERAPEUTIC use of monoclonal antibodies; HYPERLIPIDEMIA treatment
- Publication
Annals of Internal Medicine, 2017, Vol 166, Issue 3, p219
- ISSN
0003-4819
- Publication type
journal article
- DOI
10.7326/M16-1847